Dark

BHVN
Biohaven Ltd.
stock NYSE

At Close

May 23, 2025 3:59:53 PM EDT

15.62USD+1.231%(+0.19)2,288,450

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 23, 2025 9:19:30 AM EDT

15.43USD0.000%(0.00)118,355

After-hours

May 23, 2025 4:34:30 PM EDT

15.64USD+0.128%(+0.02)13,564

OverviewOptionsHistoricalExchangesShortsNews

Jan 25, 2022

07:31AM EST Biohaven's Nurtec(r) ODT Extends Partnership with Rick Ware Racing for 2022 PR Newswire

Jan 10, 2022

04:53AM EST Biohaven Announced Exclusive License and Research Collaboration Agreement with KU Leuven to Advance First-in-Class TRPM3 Antagonists for the Treatment of Pain; KU Leuven to Receive an Upfront Payment Plus Milestones Benzinga

12:09AM EST Biohaven Collaborates With KU Leuven To Advance First-in-Class TRPM3 Antagonists For The Treatment Of Pain RTTNews

12:01AM EST Biohaven Enters Exclusive License and Research Collaboration Agreement with KU PR Newswire

Jan 7, 2022

01:11PM EST Where Biohaven Pharma Hldgs Stands With Analysts Benzinga

01:04PM EST Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $148 Benzinga

Jan 6, 2022

08:24AM EST The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales Benzinga

07:02AM EST Biohaven Pharmaceuticals Reports Q4 NURTEC ODT Prelim. Sales Of $190M Benzinga

07:02AM EST BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR PR Newswire

Jan 5, 2022

07:30AM EST Biohaven Pharmaceutical Holding Company Ltd. (BHVN) and Pfizer Inc. (PFE) have completed the collaboration transaction for commercialization of Rimegepant and Zavegepant outside U.S. These agreements have become effective following the receipt of required regulatory approvals. RTTNews

07:03AM EST Biohaven, Pfizer Complete Collaboration Transaction For Commercialization Of Rimegepant And Zavegepant Outside US RTTNews

07:01AM EST Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of PR Newswire

Dec 13, 2021

07:51AM EST Biohaven Pharma Says NURTEC ODT 75 Mg Approved In Israel For Preventive Treatment Of Episodic Migraine In Adults RTTNews

07:06AM EST Biohaven's Nurtec ODT Receives Approval for Migraine Prevention in Israel Benzinga

07:02AM EST BIOHAVEN ANNOUNCES NURTEC(r) ODT RECEIVES FIRST GLOBAL APPROVAL OUTSIDE THE PR Newswire

Dec 6, 2021

07:47AM EST Biohaven Names Matthew Buten CFO; To File NDA For RTTNews

07:40AM EST Biohaven Reports Positive Topline Results From Pivotal Migraine Trial Of Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief By 15 minutes; Co. Announces 'Intranasal zavegepant 10 mg met the study's co-primary endpoints' Benzinga

07:34AM EST Biohaven Announces Positive Topline Results From Second Pivotal Clinical Trial Of Intranasal Zavegepan RTTNews

07:32AM EST Biohaven Appoints Matthew Buten As CFO, Effective By Dec 20, 2021 RTTNews

07:31AM EST Intranasal Zavegepant Demonstrating Ultra-Rapid Pain Relief by 15 minutes; Prepares for Submission of New Drug Application PR Newswire

07:29AM EST Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And Matthew Buten, Chief Financial Officer Benzinga

07:29AM EST Biohaven Names CEO Vlad Coric, MD, Chairman Of The Board Of Directors And PR Newswire

Nov 18, 2021

07:39AM EST Biohaven, Artizan Bio Report Therapeutic Development Program In Parkinson's Disease Benzinga

07:30AM EST Artizan Biosciences and Biohaven Therapeutics Announce Therapeutic GlobeNewswire Inc

07:01AM EST Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $144 Benzinga

Nov 17, 2021

07:08AM EST Biohaven Pharmaceutical Holding Company Ltd. (BHVN) said NURTEC ODT was approved by the Kuwait Ministry of Health for the acute treatment of migraine with and without aura in adults. The company noted that the approval in Kuwait is third in Middle East region, joining prior market approvals in Israel and United Arab Emirates. RTTNews

06:59AM EST Biohaven : NURTEC ODT Approved By Kuwait Ministry Of Health For Acute Treatment Of Migraine RTTNews

06:58AM EST NURTEC ODT Approved In Kuwait For Acute Treatment Of Migraine Benzinga

Nov 15, 2021

11:07AM EST Biohaven Completes Enrollment Of Verdiperstat Arm Of Pivotal Healey ALS Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital Benzinga

08:01AM EST Platform Trial Conducted By The Healey Center For ALS At Massachussetts General Hospital PR Newswire

Nov 10, 2021

12:20PM EST What 6 Analyst Ratings Have To Say About Biohaven Pharma Hldgs Benzinga

07:51AM EST Mizuho Maintains Buy on Biohaven Pharma Hldgs, Lowers Price Target to $135 Benzinga

Nov 9, 2021

11:42AM EST The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data Benzinga

11:37AM EST Biohaven And Pfizer Enter Strategic Collaboration For The Commercialization Of Rimegepant Outside The United States Benzinga

11:36AM EST Biohaven Pharmaceutical Q3 EPS $(1.91) Beats $(2.40) Estimate, Sales $135.74M Beat $128.40M Estimate Benzinga

11:25AM EST Earnings Scheduled For November 9, 2021 Benzinga

08:02AM EST Biohaven Pharmaceutical Holding Co. Ltd. (BHVN) and Pfizer Inc. (PFE) announced Tuesday a strategic commercialization arrangement for rimegepant in markets outside of the U.S., upon approval. RTTNews

07:49AM EST Biohaven, Pfizer Collaborate For Commercialization Of Rimegepant Outside U.S. RTTNews

07:47AM EST Biohaven and Pfizer Enter Strategic Collaboration for the Commercialization of PR Newswire

07:46AM EST Biohaven Reports Third Quarter 2021 Financial Results And Recent Business PR Newswire

Nov 8, 2021

08:29AM EST The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More Benzinga

Nov 4, 2021

07:31AM EDT Biohaven To Report Third Quarter 2021 Financial Results And Recent Business PR Newswire

Nov 2, 2021

07:31AM EDT Nine Line Apparel and Biohaven's Nurtec ODT Set to Honor World War II Veterans PR Newswire

Oct 27, 2021

07:41AM EDT Biohaven Reports Enrollment Of Phase 1a/1b Trial Of BHV-110 In Combo With Natural Killer Cell Therapy For Treatment Of Multiple Myeloma Benzinga

07:39AM EDT Biohaven Enrolls Phase 1a/1b Trial Of BHV-1100 In Combination With NK Cell Therapy For Treatment Of Multiple Myeloma RTTNews

07:31AM EDT ARM(tm) (Antibody Recruiting Molecule) Platform, in Combination with NK Cell Therapy for the Treatment of Multiple Myeloma PR Newswire

Oct 19, 2021

12:10PM EDT Analyst Ratings For Biohaven Pharma Hldgs Benzinga

09:31AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $145 Benzinga

Oct 6, 2021

01:48PM EDT Where Biohaven Pharma Hldgs Stands With Analysts Benzinga

08:08AM EDT Goldman Sachs Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $170 Benzinga

07:37AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

06:25AM EDT HC Wainwright & Co. Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $160 Benzinga

Oct 5, 2021

12:25PM EDT What 7 Analyst Ratings Have To Say About Biohaven Pharma Hldgs Benzinga

09:37AM EDT Piper Sandler Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $156 Benzinga

07:40AM EDT Biohaven Pharma Reports $136 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q3 RTTNews

07:31AM EDT Biohaven Prelim. Q3 Net Product Revenue From Sales Of NURTEC ODT $136M Benzinga

07:31AM EDT Biohaven Announces Preliminary 3Q2021 Net Product Revenue For NURTEC ODT, The PR Newswire

Oct 1, 2021

07:56AM EDT The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO Benzinga

Sep 27, 2021

11:42AM EDT Biohaven Pharma shares were trading lower after the company said its Phase 3 trial of Verdiperstat did not show statistically significant improvement versus the placebo for its primary efficacy measure. Benzinga

08:09AM EDT Biohaven Pharmaceutical Holding Company Ltd.'s (BHVN) verdiperstat did not statistically differentiate from placebo on the prespecified primary efficacy measure, nor on the key secondary efficacy measure, as per results from phase III trial in multiple system atrophy. RTTNews

07:34AM EDT Biohaven Says Verdiperstat Fails In Multiple System Atrophy Program RTTNews

07:02AM EDT Biohaven Pharma Says its Phase 3 Trial of Verdiperstat Did Not Statistically Differentiate from the Placebo on the Prespecified Primary Efficacy Measure Benzinga

07:01AM EDT Biohaven Provides Update On Phase 3 Trial And Multiple System Atrophy (MSA) PR Newswire

Sep 25, 2021

11:21AM EDT TENX: Second Quarter Results Benzinga

Sep 23, 2021

08:38AM EDT Biohaven Therapeutics Files For U.S. Patent Titled 'USE OF RILUZOLE PRODRUGS TO TREAT ALZHEIMER'S DISEASE' Benzinga

Sep 20, 2021

11:02AM EDT Hearing Biohaven Named New Strong Buy From Oxford Newsletter Benzinga

Sep 13, 2021

01:04PM EDT Where Biohaven Pharma Hldgs Stands With Analysts Benzinga

08:57AM EDT Cantor Fitzgerald Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $165 Benzinga

Sep 10, 2021

07:51AM EDT Cramer Gives His Opinion On Service Corporation, Vertex And More Benzinga

Sep 9, 2021

07:40AM EDT Biohaven Spotlights Nurtec ODT, Dual-therapy Indicated For Both Acute And Preventive Treatment Of Migraine, RTTNews

07:36AM EDT Biohaven Announces 17 Abstracts Will Be Shares At 2021 International Headache Society European Headache Federation Joint Congress Benzinga

07:31AM EDT for both the acute and preventive treatment of migraine, at the 2021 International Headache Society - European Headache Federation Joint Congress PR Newswire

Sep 3, 2021

07:31AM EDT The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself Benzinga

Sep 2, 2021

08:20AM EDT The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab Benzinga

Sep 1, 2021

07:32AM EDT The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering Benzinga

Aug 12, 2021

08:18AM EDT Cramer Gives His Opinion On Zillow, SoFi And More Benzinga

Aug 10, 2021

01:05PM EDT What 12 Analyst Ratings Have To Say About Biohaven Pharma Hldgs Benzinga

10:32AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2021 Benzinga

07:53AM EDT UBS Downgrades Biohaven Pharma Hldgs to Neutral, Raises Price Target to $109 Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

07:30AM EDT Biohaven Q2 Net Loss Widens To $210.6 Mln Or $3.23/shr From $180.9 Mln Or $3.08/shr Last Year RTTNews

07:27AM EDT Biohaven Pharma: Q2 Earnings Insights Benzinga

07:23AM EDT Biohaven Pharmaceutical Q2 EPS $(2.62) Beats $(2.74) Estimate, Sales $92.93M Beat $78.13M Estimate Benzinga

07:01AM EDT Biohaven Reports Second Quarter 2021 Financial Results And Recent Business PR Newswire

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 3, 2021

12:23PM EDT Where Biohaven Pharma Hldgs Stands With Analysts Benzinga

10:55AM EDT Canaccord Genuity Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $150 Benzinga

Jul 30, 2021

07:54AM EDT The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Benzinga

Jul 29, 2021

08:29AM EDT Biohaven Says Co's Nurtec ODT Signs As Official Migraine Partner Of Big Machine Music City Grand Prix Race Benzinga

07:31AM EDT Biohaven's Nurtec(r) ODT Signs as Official Migraine Partner of Big Machine PR Newswire

Jul 28, 2021

07:31AM EDT Biohaven to Report Second Quarter 2021 Financial Results and Recent Business PR Newswire

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jul 21, 2021

07:52AM EDT The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay Benzinga

Jul 16, 2021

02:50PM EDT Analyst Ratings For Biohaven Pharma Hldgs Benzinga

08:37AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $107 Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jul 12, 2021

11:42AM EDT UPDATE: Mizuho On Biohaven Pharmaceutical Price Target Raise: Firm Cites Management Confidence In Further Nurtect ODT Results & Highlights Secured Commercial Coverage Following First Year Of Launch With Market Share Gain Relative To AbbVie's Ubrelvy Benzinga

10:32AM EDT Analyst Ratings For Biohaven Pharma Hldgs Benzinga

07:54AM EDT 10 Biggest Price Target Changes For Monday Benzinga

06:50AM EDT Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $134 Benzinga

Jul 9, 2021

07:36AM EDT The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO Benzinga

Jul 8, 2021

11:43AM EDT Analyst Ratings For Biohaven Pharma Hldgs Benzinga

07:51AM EDT HC Wainwright & Co. Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $135 Benzinga

07:45AM EDT The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test Benzinga

Jul 7, 2021

09:53AM EDT Shares of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) jumped over 10% on Wednesday morning after the company reported its migraine drug generated $93 million in sales. RTTNews

07:41AM EDT The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend Benzinga

07:09AM EDT Biohaven Reports Q2 NURTEC ODT Sales of $93M Benzinga

07:01AM EDT Biohaven Announces Preliminary 2Q2021 Net Product Revenue For NURTEC ODT, The PR Newswire

Jun 23, 2021

10:48AM EDT Biohaven Pharmaceutical: Return On Capital Employed Insights Benzinga

03:00AM EDT Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP PR Newswire

Jun 18, 2021

10:05AM EDT Biohaven Shares Rebound From Session Low; Traders Circulate Speculation From Dealreporter Co. Could Be Setting Up For A Sale Benzinga

Jun 17, 2021

04:06PM EDT Biohaven Appoints Kishen Mehta To Board Of Directors RTTNews

Jun 15, 2021

02:31PM EDT Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study Benzinga

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

Jun 9, 2021

01:58PM EDT Biohaven Pharma Hldgs Option Alert: Oct 15 $100 Calls at the Ask: 2450 @ $11.5 vs 339 OI; Ref=$96.03 Benzinga

Jun 8, 2021

12:35PM EDT Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network Business Wire

Jun 7, 2021

10:02AM EDT Biohaven Pharmaceutical Insights: Return On Capital Employed Benzinga

Jun 3, 2021

07:31AM EDT (rimegepant), Now Approved to Treat and Prevent Migraine Attacks, and Zavegepant with 19 Presentations at the 2021 Virtual Annual Scientific Meeting of the American Headache Society PR Newswire

Jun 1, 2021

11:03AM EDT Analyst Ratings for Biohaven Pharma Hldgs Benzinga

08:04AM EDT Cantor Fitzgerald Maintains Overweight on Biohaven Pharma Hldgs, Raises Price Target to $140 Benzinga

May 28, 2021

10:11AM EDT Mizuho Maintains Buy on Biohaven Pharma Hldgs, Raises Price Target to $92 Benzinga

08:02AM EDT The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq Benzinga

08:00AM EDT Biohaven's Nurtec Wins FDA Approval As First Med to Prevent and Treat Migraine Attacks Benzinga

May 27, 2021

04:17PM EDT Biohaven Announces FDA Approval Of NURTEC ODT Benzinga

04:16PM EDT FDA Approves Biohaven's NURTEC(r) ODT (rimegepant) for Prevention: Now the PR Newswire

May 18, 2021

09:16AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Lowers Price Target to $69 Benzinga

May 14, 2021

07:31AM EDT Biohaven's Nurtec(r) ODT Signs as Primary Partner with Rick Ware Racing for PR Newswire

May 12, 2021

07:45AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

06:17AM EDT SVB Leerink Maintains Outperform on Biohaven Pharma Hldgs, Lowers Price Target to $105 Benzinga

May 11, 2021

10:43AM EDT Mizuho Maintains Buy on Biohaven Pharma Hldgs, Lowers Price Target to $90 Benzinga

07:31AM EDT Unable to Control Disease and Dissatisfied with Current Preventive Treatment Options PR Newswire

May 10, 2021

04:09PM EDT /C O R R E C T I O N -- Biohaven Pharmaceutical Holding Company Ltd./ PR Newswire

10:06AM EDT Biohaven Pharmaceutical shares were trading lower after the company reported worse-than-expected Q1 EPS results. Benzinga

08:11AM EDT Biohaven Pharmaceutical Q1 Net Loss $261.0 Mln Vs. Net Loss $172.9 Mln Last Year RTTNews

08:00AM EDT Recap: Biohaven Pharma Q1 Earnings Benzinga

07:34AM EDT Biohaven Pharmaceutical Q1 EPS $(2.97) Misses $(2.82) Estimate, Sales $43.82M Beat $40.63M Estimate Benzinga

07:31AM EDT Biohaven Reports First Quarter 2021 Financial Results and Recent Business PR Newswire

04:09AM EDT Earnings Scheduled For May 10, 2021 Benzinga

Apr 28, 2021

07:31AM EDT Biohaven to Report First Quarter 2021 Financial Results and Recent Business PR Newswire

Apr 26, 2021

09:51AM EDT Mizuho Maintains Buy on Biohaven Pharma Hldgs, Lowers Price Target to $98 Benzinga

Apr 19, 2021

09:21AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharma Hldgs, Raises Price Target to $76 Benzinga

Apr 14, 2021

11:51AM EDT TENX: HELP Results & New Asset to Boot Benzinga

Apr 13, 2021

07:40AM EDT Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology Virtual Annual Meeting Benzinga

07:35AM EDT Biohaven Pharma Highlights Neuroscience Advancements With 22 Presentations RTTNews

07:31AM EDT Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 PR Newswire

Apr 7, 2021

07:36AM EDT Biohaven Reports $43.8 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q1 RTTNews

07:33AM EDT Biohaven Sees Prelim. Q1 NURTEC ODT Net Product Revenue $43.8M Benzinga

07:30AM EDT Biohaven Announces Preliminary 1Q2021 Net Product Revenue For NURTEC ODT PR Newswire

Apr 6, 2021

07:31AM EDT Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen PR Newswire

Mar 29, 2021

11:33AM EDT Biohaven Secures $100M Milestone Funding After Enrolling First Patient In Migraine Study With Oral Zavegepant Benzinga

07:34AM EDT Biohaven Enrolls First Patient In Phase 2/3 Trial Of Oral Zavegepant For The Preventive Treatment Of Migraine RTTNews

07:32AM EDT Biohaven Enrolls First Patient in Phase 2/3 Trial Of Oral Zavegepant, Prompting $100M Milestone Funding Payment Fom Royalty Pharma Benzinga

07:31AM EDT Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting PR Newswire

Mar 21, 2021

07:39AM EDT The Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More Benzinga

Mar 16, 2021

08:17AM EDT The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study Benzinga

Mar 15, 2021

10:48PM EDT Biohaven Prices Underwritten Public Offering Of 2.69 Mln Shares At $76.00/shr RTTNews

10:17PM EDT Biohaven Announces Pricing Of $200 Million Public Offering Of Common Shares PR Newswire

04:33PM EDT Biohaven Announces Proposed Public Offering $200M Of Common Stock Benzinga

04:33PM EDT Biohaven Announces Proposed Public Offering Of Common Shares PR Newswire

Mar 11, 2021

11:21AM EST ROCE Insights For Biohaven Pharmaceutical Benzinga

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 11, 2021 Benzinga

08:37AM EST UBS Initiates Coverage On Biohaven Pharma Hldgs with Buy Rating, Announces Price Target of $108 Benzinga

07:48AM EST Biohaven: NURTEC ODT Approved By United Arab Emirates Ministry Of Health And Prevention For Acute Treatment Of Migraine RTTNews

07:35AM EST Biohaven's NURTEC ODT Approved In United Arab Emirates For Acute Treatment Of Migraine Benzinga

07:31AM EST Biohaven's NURTEC(r) ODT Approved In United Arab Emirates For Acute Treatment PR Newswire

Mar 10, 2021

06:23PM EST Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital PR Newswire

07:34AM EST Biohaven And Medison Pharma: NURTEC ODT Approved By Israeli Ministry Of Health For Acute Treatment Of Migraine RTTNews

07:33AM EST Biohaven's NURTEC ODT Approved In Israel For Acute Treatment Of Migraine Benzinga

Mar 1, 2021

04:00PM EST Agreement enables Biohaven to exercise option on up to three of Artizans candidates for the treatment of inflammatory bowel disease GlobeNewswire Inc

07:59AM EST Recap: Biohaven Pharmaceutical Q4 Earnings Benzinga

07:45AM EST Biohaven Q4 Adj. Net Loss $161.7 Mln Or $2.69/shr Vs. Loss $124.4 Mln Or $2.38/shr Prior Year RTTNews

07:33AM EST Biohaven Pharmaceutical Q4 EPS $(2.69) Beats $(2.97) Estimate, Sales $35.11M Beat $28.23M Estimate Benzinga

07:31AM EST Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent PR Newswire

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 23, 2021

06:41PM EST Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And PR Newswire

Feb 22, 2021

12:25PM EST Biohaven Pharma's BHV-1200 Effective In Neutralizing COVID-19 Variants Benzinga

07:36AM EST Biohaven's Multimodal Antibody Therapy Enhancer BHV-1200 Shows Effective Neutralization Of Multiple Strains Of COVID-19 RTTNews

07:32AM EST Biohaven Says Its BHV-1200 Multimodal Antibody Therapy Enhancer Has 'demonstrated functional binding and neutralization of the SARS-CoV-2 virus' Including UK And South Africa Variants Benzinga

07:30AM EST Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19 PR Newswire

Feb 8, 2021

07:31AM EST Biohaven Provides Update On ESG Practices PR Newswire

Jan 25, 2021

07:42AM EST Biohaven Reports $35 Mln In Net Product Revenue From Sales Of NURTEC ODT In Q4, Represents 98% Increase Prior Quarter RTTNews

07:37AM EST Biohaven Sees Prelim. Q3 NURTEC ODT Revenue Of $35M Benzinga

07:31AM EST Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC(r) ODT PR Newswire

Jan 19, 2021

11:12AM EST Biohaven shares were trading lower after the company on Monday reported at 48 weeks troriluzole did not statistically differentiate from placebo on its Phase 2/3 trial's prespecified co-primary endpoints and key secondary measure. Benzinga

06:17AM EST HC Wainwright & Co. Maintains Buy on Biohaven Pharmaceutical, Lowers Price Target to $111 Benzinga

Jan 18, 2021

10:10AM EST Biohaven Signs Cody Ware as Driver for Nurtec(r) ODT Chevrolet for the 2021 PR Newswire

09:01AM EST Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program PR Newswire

Jan 8, 2021

07:11AM EST Cramer Advises Viewers On Autodesk, Inseego And More Benzinga

Jan 7, 2021

07:46AM EST Biohaven Announces Acquisition Of Remaining 58% Interest Of Kleo Pharmaceuticals RTTNews

07:35AM EST Biohaven Also Announces Execution Of Exclusive License Agreement With Yale For Novel Extracellular Degrader Technology Benzinga

07:34AM EST Biohaven Acquires Remaining 58% Of Kleo Pharmaceuticals In Stock Deal Valuing Kleo, Including Cash On Hand, At ~$20M Benzinga

07:31AM EST Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From PR Newswire

Jan 5, 2021

10:01AM EST Biohaven's Nurtec(r) ODT Partners with Rick Ware Racing for 24 Hours of Daytona PR Newswire

Jan 4, 2021

07:34AM EST Biohaven Commences Enrollment In Phase 3 Clinical Trial Assessing Efficacy And Safety Of Troriluzole RTTNews

07:32AM EST Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder Benzinga

07:31AM EST Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive PR Newswire

Dec 23, 2020

04:24PM EST Biohaven Filing Shows Registration For $00M Common Stock Shelf Offering Benzinga

Dec 16, 2020

12:21PM EST Morgan Stanley Maintains Equal-Weight on Biohaven Pharmaceutical, Raises Price Target to $73 Benzinga

07:33AM EST Biohaven Highlights Publication Of Phase 3 Trial Of Rimegepant In The Lancet Benzinga

07:32AM EST Biohaven Says The Lancet Published Positive Results From A Phase 3 Clinical Trial Of Rimegepant RTTNews

07:31AM EST Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The PR Newswire

Dec 15, 2020

09:42AM EST Benzinga's Top Upgrades, Downgrades For December 15, 2020 Benzinga

06:09AM EST HC Wainwright & Co. Initiates Coverage On Biohaven Pharmaceutical with Buy Rating, Announces Price Target of $121 Benzinga

Dec 7, 2020

10:00AM EST Kleo Pharmaceuticals, Inc., a targeted immunotherapy company developing fully synthetic bispecific therapies to redirect, enhance or replace antibodies, is presenting preclinical data today on KPMW135, a novel CD3 x CD20 bispecific molecule developed with Kleos multi-targeted antibody therapy enhancer (MATE) conjugation platform. GlobeNewswire Inc

06:59AM EST SVB Leerink Maintains Outperform on Biohaven Pharmaceutical, Raises Price Target to $120 Benzinga

Dec 2, 2020

10:05AM EST Biohaven's Nurtec(tm) ODT Partners with the Rick Ware Racing Team in the 2021 PR Newswire

Nov 30, 2020

08:00AM EST Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a GlobeNewswire Inc

Nov 28, 2020

01:46PM EST Notable Insider Buys in the Past Week: Biglari, Coty, Danaher, Foot Locker And More Benzinga

Nov 22, 2020

09:32PM EST BioShinLimited announced today that the first patients were enrolled in its regional multi-center study, BHV3000-310, being conducted in China and Korea. BHV3000-310 is a double-blind, randomized trial evaluating the safety and efficacy of rimegepant in the acute treatment of migraine. GlobeNewswire Inc

Nov 18, 2020

06:46PM EST Vlad Coric On CNBC: We Are Optimistic About Upcoming Data Release On Troriluzole For Alzheimer's Disease Benzinga

06:44PM EST Vlad Coric On CNBC: The Preventative Form Of NURTEC Is The Same Drug As The Treatment Form, No New Side Effects, Just A Different Dosing Pattern Benzinga

06:43PM EST Vlad Coric On CNBC: I Think In 6 Months We Will Be The First Oral CGRP Indicated For The Prevention Of Migraines, We Have Filed SNDA With FDA, Have PDUFA Date Next Year Benzinga

06:42PM EST Biohaven CEO Vlad Coric On CNBC: Our NURTEC OTD Migraine Drug Blocks CGRP To Block Migraine Pain Benzinga

Nov 17, 2020

09:52AM EST Stocks Trading Near 52-Week Highs Just After Open On Tuesday, Nov. 17, 2020: CAPA, FSRVU, TRTN, ATRA, BEEMW, COOP, NBACU, STKL, KLAC, DLB, PCGU, GNTX, CSV, CCCC, DAC, BHVN, DTP, ACHC, GM, QCOM, FOLD, SNX, GRWG, CHI, CHY, UPWK Benzinga

Nov 16, 2020

11:30AM EST Canaccord Genuity Maintains Buy on Biohaven Pharmaceutical, Raises Price Target to $110 Benzinga

09:07AM EST Biohaven Pharmaceuticals Announces Value-Based Agreement With Prime Therapeutics To Bring NURTEC ODT Acute Migraine Treatment Financial Protection To Health Plans Benzinga

09:00AM EST NURTEC(tm) ODT acute migraine treatment financial protection to health plans PR Newswire

07:34AM EST Biohaven Pharma, Weill Cornell Medicine Report Collaboration To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis Benzinga

07:31AM EST Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate PR Newswire

Nov 13, 2020

07:40AM EST The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations Benzinga

Nov 12, 2020

07:44AM EST The Daily Biotech Pulse: AstraZeneca's Cancer Drug Flunks COVID-19 Studies, Five Prime On a Roll, Morphosys, Xencor, Incyte Strike Cancer Deal Benzinga

Nov 11, 2020

04:30PM EST Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug PR Newswire

Nov 9, 2020

08:32AM EST Recap: Biohaven Pharmaceutical Q3 Earnings Benzinga

08:11AM EST Biohaven Q3 Loss/shr $3.27 Vs. Loss/shr $2.04 Last Year RTTNews

08:07AM EST Biohaven Pharmaceutical Q3 EPS $(3.27) Misses $(2.89) Estimate, Sales $17.66M Miss $19.84M Estimate Benzinga

08:02AM EST Biohaven Reports Third Quarter 2020 Financial Results and Recent Business PR Newswire

08:00AM EST Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on GlobeNewswire Inc

04:13AM EST Earnings Scheduled For November 9, 2020 Benzinga

Nov 8, 2020

03:58PM EST The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions Benzinga

12:47PM EST The Week Ahead In Biotech: Earnings, Conference Presentations And IPOs Benzinga

Nov 5, 2020

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

Nov 4, 2020

08:21AM EST The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings Benzinga

Oct 30, 2020

06:24PM EDT Biohaven To Report Third Quarter 2020 Financial Results And Recent Business PR Newswire

Oct 14, 2020

07:33AM EDT FDA Accepts Biohaven's Supplemental New Drug Application Of NURTEC ODT For The Preventive Treatment Of Migraine Benzinga

07:33AM EDT FDA Accepts Biohaven's SNDA Of NURTEC ODT For Preventive Treatment Of Migraine RTTNews

07:31AM EDT U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of PR Newswire

Oct 13, 2020

08:30AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharmaceutical, Raises Price Target to $63 Benzinga

Sep 28, 2020

07:01AM EDT BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to PR Newswire

Sep 21, 2020

08:00AM EDT Kleo Pharmaceuticals to Present at Bioscience GlobeNewswire Inc

Sep 10, 2020

09:37AM EDT Biohaven's Oral Zavegepant Gets Authorization To Proceed From FDA And Achieves First In Human Dosing RTTNews

09:37AM EDT Biohaven Pharmaceutical Holding Company Ltd. (BHVN) announced the FDA has authorized the initiation of clinical trials for oral zavegepant. Biohaven Pharma said it has achieved first in human dosing in a phase 1 trial designed to assess the safety and pharmacokinetics of oral formulations of zavegepant. RTTNews

07:04AM EDT Biohaven's Oral Zavegepan Receives Authorization To Proceed From FDA And Achieves First In Human Dosing Benzinga

Sep 8, 2020

08:37AM EDT Biohaven Pharma Investment, Kleo Pharma, Reports Orphan Drug Designation For KP1237 In Multiple Myeloma Benzinga

08:30AM EDT Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 GlobeNewswire Inc

Aug 24, 2020

07:52AM EDT Morgan Stanley Maintains Equal-Weight on Biohaven Pharmaceutical, Lowers Price Target to $57 Benzinga

Aug 10, 2020

09:44AM EDT Biohaven Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. The stock has reversed and is now trading lower. Benzinga

07:50AM EDT Biohaven Pharmaceutical Q2 EPS $(2.55) Beats $(2.61) Estimate, Sales $9.70M Beat $7.65M Estimate Benzinga

document.getElementById("JgPHBf").onerror = function(){this.style.display='none';}; .dark-mode .JKhSYX{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .JKhSYX{ color: #333333; background-color: white; border: 2px solid #333333; }BHVNBiohaven Ltd.stock NYSE

BHVN
Biohaven Ltd.
stock NYSE